Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

iseases, including SJIA[5]. ACZ885 works by neutralizing IL-1 beta for a sustained period of time, therefore inhibiting inflammation.

ACZ885 is currently approved in the US and other countries for a different disease state.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "can," "on track," "potentially," "will," "planned," "may," "committed," "potential," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for ACZ885 or regarding potential future revenues from ACZ885. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with ACZ885 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that ACZ885 will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that ACZ885 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding ACZ885 could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; unexpected manufacturing issues, the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Hussey Copper , a ... antimicrobial copper announces Pullman Regional Hospital,s conversion of ... antimicrobial solid touch surface, at a nominal cost.  This ... E-coli and other bacteria within 2 hours of exposure 1 ... bacteria and infectious diseases in its facilities. ...
(Date:7/22/2014)... 22, 2014  United Therapeutics Corporation (NASDAQ: ... release its second quarter 2014 financial results before ... United Therapeutics will host a half-hour teleconference ... Eastern Time.  The teleconference is accessible by dialing ... of the teleconference will be available for one ...
(Date:7/22/2014)... 2014 Dr. Williams says, “Bush has ... recognized that the greatest health care system in the ... needlessly deadly while trying to serve the public. Unfortunately, ... to transform an enormous system that none of them ... his continuing series of Open Letters ( http://is.gd/wdU2CM ) ...
(Date:7/21/2014)... yield so far is small, but chemists at the ... substitution process to make a precursor to transparent thin ... energy devices. , A paper describing the approach is ... of the journal Inorganic Chemistry , which draws ... nuclear chemistry fields. The paper was chosen by the ...
Breaking Biology Technology:Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Oregon chemists eye improved thin films with metal substitution 2
... , , ROCKVILLE, Md., July 21 ... appointment of John J. Trizzino as Senior Vice President, International ... Trizzino will report directly to Dr. Rahul Singhvi, Novavax,s President ... managing the company,s international alliances with pharmaceutical companies and all ...
... ... is pleased the U.S. Environmental Protection Agency will allow farmers the ability to improve upon ... for SmartStax, an insect-protection and weed control platform in corn, to 5 percent in the ... ...
... , , NEWARK, N.J., July 21 ... a specialty chemical technology based Life Science Company announced ... protocol testing, BioNeutral,s Ygiene(TM) Hospital Grade Antimicrobial passed the ... all 5.4 million spores of Clostridium difficile ...
Cached Biology Technology:Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances 2EPA Refuge Determination Positive for the Environment 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3
(Date:7/22/2014)... of planthopper known as Conosimus, which now includes six ... the southern part of the Iberian Peninsula in the ... in the open-access Journal of Insect Science ... Conosimus baenai , has been named after Manuel Baena, ... of Iberian Hemiptera. , Conosimus baenai differs ...
(Date:7/21/2014)... a professor of entomology and cooperating faculty ... the University of California, Riverside, has been awarded the ... of Chemical Ecology ( ISCE ). , Awarded first ... the society,s highest honor. It is awarded annually to ... the study of chemicals that mediate interactions between living ...
(Date:7/21/2014)... to monitor seals, every movement, researchers have shown for ... to offshore wind farms and pipelines. Those man-made structures ... according to a study published in the Cell Press ... , "I was shocked when I first saw the ... Shoal," an offshore wind farm in the United Kingdom, ...
Breaking Biology News(10 mins):UC Riverside entomologist receives international honor for chemical ecology contributions 2Seals forage at offshore wind farms 2
... Researchers speaking in the first plenary session of the ... (IAS 2011) have today offered insights into current and ... developments over the past two years are beginning ... policy. The presentations reflect the breadth of expertise ...
... trailing a long length of rope behind you is not ... to manoeuvre, and can get tangled up or stuck on ... apart during cell division. The chromosomes are pulled by their ... Just like climbers carry their rope coiled up, cells make ...
... PHILADELPHIA The use of trastuzumab, chemotherapy and ... improved survival from the time central nervous system metastases ... researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now ... chemotherapy, even if cancer spreads to the brain." ...
Cached Biology News:Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 2Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 3Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 4Keeping it together 2Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients 2